MARKET

MRUS

MRUS

Merus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

25.30
-0.26
-1.02%
Opening 13:08 09/16 EDT
OPEN
25.33
PREV CLOSE
25.56
HIGH
25.90
LOW
24.82
VOLUME
21.16K
TURNOVER
--
52 WEEK HIGH
31.27
52 WEEK LOW
11.19
MARKET CAP
973.49M
P/E (TTM)
-9.2987
1D
5D
1M
3M
1Y
5Y
Those who invested in Merus (NASDAQ:MRUS) five years ago are up 173%
When you buy a stock there is always a possibility that it could drop 100%. But on a lighter note, a good company can...
Simply Wall St. · 09/07 13:33
Merus to Participate in Upcoming Investor Conferences
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bi...
GlobeNewswire · 09/07 12:00
Vivo Capital, LLC Buys ALX Oncology Holdings Inc, Bolt Biotherapeutics Inc, Bolt ...
GuruFocus News · 08/23 22:38
Silverarc Capital Management, Llc Buys Chinook Therapeutics Inc, Amryt Pharma PLC, Mirati ...
GuruFocus News · 08/23 06:28
Merus N.V. (MRUS) Reports Q2 Loss, Tops Revenue Estimates
Zacks.com · 08/06 01:05
BRIEF-Merus Qtrly Loss Per Share $0.71
reuters.com · 08/05 22:30
Merus Q2 EPS $(0.71) Down From $(0.54) YoY, Sales $12.38M Up From $6.06M YoY
Merus (NASDAQ:MRUS) reported quarterly losses of $(0.71) per share. This is a 31.48 percent decrease over losses of $(0.54) per share from the same period last year. The company reported $12.38 million in sales this
Benzinga · 08/05 22:16
Merus EPS misses by $0.13, beats on revenue
Merus (NASDAQ:MRUS): Q2 GAAP EPS of -$0.71 misses by $0.13. Revenue of $12.38M (+103.0% Y/Y) beats by $4.32M. Press Release
Seekingalpha · 08/05 21:20
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MRUS. Analyze the recent business situations of Merus through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MRUS stock price target is 30.63 with a high estimate of 34.00 and a low estimate of 21.00.
EPS
Institutional Holdings
Institutions: 80
Institutional Holdings: 30.14M
% Owned: 78.33%
Shares Outstanding: 38.48M
TypeInstitutionsShares
Increased
22
1.79M
New
15
784.55K
Decreased
15
553.21K
Sold Out
8
1.97M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.01%
Pharmaceuticals & Medical Research
-0.38%
Key Executives
Non-Executive Chairman/Independent Director
Anand Mehra
President/Chief Executive Officer/Chief Financial Officer/Executive Director
Sven Lundberg
Non-Executive Vice Chairman/Non-Executive Director
Gregory Perry
Chief Technology Officer
Cornelis Adriaan de Kruif
General Counsel
Peter Silverman
Other
Alexander Bakker
Other
Andrew Joe
Other
Hui Liu
Non-Executive Independent Director
Mark Iwicki
Non-Executive Independent Director
Leonard Kanavy
Non-Executive Independent Director
Paolo Pucci
Non-Executive Independent Director
Victor Sandor
No Data
About MRUS
Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products include, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as well as MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.

Webull offers kinds of Merus NV stock information, including NASDAQ:MRUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRUS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRUS stock methods without spending real money on the virtual paper trading platform.